Finally, we consider the potential to exploit the chemical matter arising from these activities in combination screens and permeation assays which are designed to confirm mechanism of action (MoA), elucidate potential synergies in polypharmacy, and to develop rules for drug permeability in an organism that poses a special challenge to new drug development.
Hence, an improvement in chemical property representation for the visualization of compound combination screens is still very much desirable, which is the objective of the current work.
We highlight cutting-edge systems approaches, including large-scale modeling of cell signaling networks, network motif analysis, statistical association-based models, identifying correlations in gene signatures, functional genomics, and high-throughput combination screens.
Additionally, preclinical drug combination screens explore various concentration ranges for each drug in a combination, making the exhaustive screen of all possible drug combinations difficult.
Zinner et al. developed another drug combination screening model called Medicinal Algorithmic Combinational Screen (MACS) and have screened 72 combinations of arbitrary size and formed a 19-element drug pool across four generations.
Rickles RJ, Tam WF, Giordano TP, Pierce LT, Farwell M, McMillin DW, Necheva A, Crowe D, Chen M, Avery W, Kansra V, Nawrocki ST, Carew JS, Giles FJ, Mitsiades CS, Borisy AA, Anderson KC, Lee MS. Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening.
A new visualization technique for pairwise combination screening data, termed "Synergy Maps", is presented.
These methods include computational modeling, gene signature analysis, functional genomics, and high-throughput drug combination screening.
in vitro [73] Lymphoma Drug combination screen Screen of 500 compounds with ibrutinib revealed favorable combinations with inhibitors of PI3K signaling, the Bcl2 family, and B-cell receptor pathway in vitro [74] Various cancers Drug combination screen Screen of 5,000 combinations of FDA-approved drugs in the NCI-60 cancer cell line panel.
One of the major ongoing initiatives at the Developmental Therapeutics Program of the National Cancer Institute, U.S. National Institute of Health, is the large-scale high-throughput drug combination screening of 100 FDA approved drugs.
This "combination screen" was identical to a standard F2 screen with the exception that the crosses were designed to identify synthetic lethal interactions with Smn in the F1.
